Can-Fite Advances Phase III Programs With FDA and EMA Status
RAMAT GAN, Israel, August 12, 2026 Can-Fite BioPharma Ltd. announced an update on the regulatory status of its two...
plaque psoriasis
Advertisement
Alumis Advances Envudeucitinib With 54% PASI 100 Response
SOUTH SAN FRANCISCO, California, August 10, 2026 Alumis Inc. announced topline long-term results from the ongoing Phase 3 ONWARD3...
Philips Reports Strong Q2 2026 Growth and AI Innovation
Amsterdam, Netherlands, July 27, 2026 Royal Philips has reported solid second-quarter 2026 financial results, driven by 4% comparable sales...
InnoCare Phase III TYK2 Study Meets Psoriasis Endpoint
Beijing, July 27, 2026 InnoCare Pharma has announced that its novel TYK2 (Tyrosine Kinase 2) inhibitor fadeucravacitinib (ICP-488) successfully...
Takeda Reports Strong Phase 3 Zasocitinib Results
Osaka, Japan & Cambridge, Mass., July 16, 2026 Takeda announced new Phase 3 data demonstrating that its investigational oral...
Advertisements
Can-Fite Completes Phase 3 Psoriasis Trial Enrollment
RAMAT GAN, Israel, July 6, 2026 Can-Fite BioPharma announced the completion of enrollment of the first 247 patients in...
Junshi Biosciences Expands Roconkibart Through Fosun Alliance
Shanghai, China, July 1, 2026 Junshi Biosciences has entered into a landmark licensing collaboration with Fosun Wanbang Pharma Group,...
Arcutis Secures FDA Approval for ZORYVE in Children Aged 2+
WESTLAKE VILLAGE, Calif., June 29, 2026 Arcutis Biotherapeutics, Inc. announced that the U.S. Food and Drug Administration (FDA) has...
AbbVie Secures FDA Approval for SKYRIZI in Pediatric Psoriatic Disease
NORTH CHICAGO, Ill., June 26, 2026 AbbVie announced that the U.S. Food and Drug Administration (FDA) has approved SKYRIZI®...
Akeso Wins NMPA Approval for Gumokimab in Plaque Psoriasis
HONG KONG, June 11, 2026 Akeso, Inc. announced that China’s National Medical Products Administration (NMPA) has approved gumokimab (AK111,...
Advertisement
